Skip to main content
. 2022 Nov 16;13:1005321. doi: 10.3389/fimmu.2022.1005321

Figure 4.

Figure 4

Broader neutralizing antibodies against SARS-CoV-2 variants were induced by RBD-mFc intranasal immunization. The cross-reactive neutralization of immune sera against wild-type and variants of SARS-CoV-2 was analyzed by pseudovirus neutralization. (A–C) Neutralization titers for wild-type and VOC pseudoviruses generated by immune sera from the (A) RBD/i.n., (B) RBD-mFc/i.n. and (C) RBD-mFc/i.m. groups 14 days after the 2nd boost immunization. The majority of immune sera showed broad-spectrum neutralization capacity. All groups n=4. The dotted lines represent the limit of detection (1:20 dilution). Geometric mean titers calculated by GraphPad Prism are shown above each column. (D) Comparison of neutralization titers against individual viruses between immune sera from the RBD/i.n., RBD-mFc/i.n. and RBD-mFc/i.m. groups. Data are presented as the mean ± SD; nonparametric ANOVA with Dunn’s multiple comparison test was used to test for significant differences in (A). Significant differences in (B–D) were determined by one-way ANOVA with Tukey’s multiple comparisons test. *p < 0.05.